Scientists probe why some melanoma patients respond to immunotherapy
NCT ID NCT02626065
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at 32 people with advanced melanoma who were treated with the immunotherapy drug Nivolumab. Researchers took blood samples before and during treatment to track changes in immune cells. The goal was to find differences between patients whose tumors shrank or stayed stable and those whose cancer kept growing, which could lead to better treatment strategies.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Nivolumab
- What this could lead to
- If successful, this could help doctors predict which melanoma patients will benefit from Nivolumab and improve treatment strategies.
- What could go wrong
- This is a small, completed study focused on understanding immune responses, not testing a new treatment. Results may not lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
32 people
The number who actually took part.
- Started
-
Apr 2015
- Finished
-
Dec 2017
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Men and women aged ≥ 18 years * Patient with metastatic or unresectable melanoma * Anti-PD1 monoclonal antibodies treatment indication * Patient affiliated to a social security regime * Signed Written Informed Consent. * agree with the storage of his biological samples * Women of childbearing potential must as mentioned in the summary of product characteristics (SPC) using two effective methods of contraception during treatment, and men whose partner is of childbearing potential must use effective contraception during treatment. For all patients treated men and women, contraception should be continued during the four months following the discontinuation of nivolumab. Exclusion Criteria: * development of haematological tumor during treatment * Patients requiring concomitant chronic treatment with systemic corticosteroids or other immunosuppressive agents * Patients with autoimmune disease. * Patient with Occular melanoma
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Metastatic melanoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69310, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Real-World melanoma care under the microscope
- New antibody aims to preserve immune checkpoint while fighting cancer
- Can a DNA vaccine teach the immune system to hunt melanoma?
- Can an immune booster make chemo hit melanoma harder?
- A quest to find biomarkers that match melanoma patients with the right immunotherapy
- Can a triple immunotherapy attack beat advanced melanoma?